AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today multiple peer-reviewed publications that provide further evidence of the safety, clinical effectiveness, and mechanisms of action of Targeted Lung Denervation (TLD) therapy in COPD. The company’s dNerva® Lung […]
3750 Annapolis Lane North
Minneapolis, MN 55447
© 2019 Nuvaira Inc. All rights reserved.
Nuvaira Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).